Climb Bio, Inc. (CLYM) Research

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Market snapshot

Symbol
CLYM
Price
$11.45
Day change
+0.97%
Market cap
$780.7M
P/E ratio
-14.79x
52-week range
1.17-12.48
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$21.67

Recent news

  • Why Is Climb Bio Stock Gaining Friday?

    Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets.

Peer companies

  • Acumen Pharmaceuticals, Inc. (ABOS)
  • Actuate Therapeutics Inc (ACTU)
  • Agenus Inc. (AGEN)
  • Anixa Biosciences, Inc. (ANIX)
  • Entera Bio Ltd. (ENTX)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Seres Therapeutics, Inc. (MCRB)
  • Spero Therapeutics, Inc. (SPRO)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — A-Award (40000 shares) on 2026-06-05
  • Levin Andrew David — A-Award (40000 shares) on 2026-06-05
  • Drapkin Kimberlee C — A-Award (40000 shares) on 2026-06-05
  • WILLIAMS DOUGLAS E — A-Award (40000 shares) on 2026-06-05
  • Cumbo Alexander — A-Award (40000 shares) on 2026-06-05

Open Climb Bio, Inc. (CLYM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.